Norditropin Flexpro (Somatropin)

Somatropin mimics natural growth hormone by binding to growth hormone receptors on cells, triggering the JAK2‑STAT5 pathway. This leads to increased production of insulin‑like growth factor‑1 (IGF‑1) in the liver, which drives growth of bone, cartilage, and muscle, while also influencing metabolism and protein synthesis throughout the body.

The dose of Norditropin FlexPro is individualized. A qualified prescriber determines the appropriate amount based on the patient’s age, weight, underlying condition, and treatment goals. Dosing regimens are tailored during clinical evaluation and may be adjusted over time according to response and safety monitoring.

The safety of Norditropin FlexPro in pregnancy and lactation has not been definitively established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, cold‑chain shipping details (if needed) and assists with import documentation.

Norditropin FlexPro is a recombinant human growth hormone formulated in a pre‑filled pen for subcutaneous injection, offering convenient dosing and precise dose selection. Compared with vial‑based products, the pen device reduces preparation steps and dosing errors. Efficacy and safety are comparable across approved somatropin brands when used as directed.

Norditropin FlexPro must be stored in a refrigerator at 2‑8 °C (36‑46 °F). Keep the pen in its original packaging, protect it from light, and avoid freezing or shaking. If the product reaches room temperature, it may be used for a limited period as indicated in the product labeling.

The medication is delivered subcutaneously using the pre‑filled pen. The prescriber selects the appropriate dose, and the patient or caregiver injects into a fatty tissue area such as the thigh, abdomen or upper arm. Injection technique, site rotation and hygiene are essential for optimal absorption and to minimize local reactions.

Serious risks include intracranial hypertension, slipped epiphysis (growth plate injury), severe allergic reactions, and pancreatitis. Patients should be monitored for persistent headaches, visual changes, joint pain, or abdominal symptoms, and any concerning signs should prompt immediate medical evaluation.

Norditropin FlexPro is contraindicated in individuals with known hypersensitivity to somatropin or any excipients, active malignancy, or acute critical illness. It should also be avoided in patients with uncontrolled diabetes or severe edema without appropriate medical supervision. Clinicians must assess each patient’s medical history before initiating therapy.